| 阿帕替尼治疗晚期胃癌的临床疗效观察 |
| |
| 引用本文： | 韩婷婷1,石明伟2,王 凡1,王颖杰3. 阿帕替尼治疗晚期胃癌的临床疗效观察[J]. 现代肿瘤医学, 2018, 0(4): 557-559. DOI: 10.3969/j.issn.1672-4992.2018.04.018 |
| |
| 作者姓名： | 韩婷婷1 石明伟2 王 凡1 王颖杰3 |
| |
| 作者单位： | 1.安徽医科大学第一附属医院肿瘤放疗科，安徽 合肥 230022；2.中国科学院合肥肿瘤医院肿瘤科，安徽 合肥 230031；3.解放军空军总医院放疗科，北京 100142 |
| |
| 摘 要： | 目的:探讨阿帕替尼治疗晚期胃癌患者的临床疗效和安全性。方法:回顾性分析我院2016年1月至2017年2月接受阿帕替尼治疗的28例化疗失败的胃癌患者，给予阿帕替尼500 mg/d，直至患者出现疾病进展或不可耐受的不良反应，分析其疗效和安全性。结果:阿帕替尼治疗晚期胃癌的有效率（RR）为10.7%，疾病控制率（DCR）为42.8%，中位无进展生存时间（PFS）为3.6个月，中位总生存时间（OS）为5个月，患者耐受性良好，常见的不良反应为高血压、手足综合征和蛋白尿。结论:阿帕替尼治疗二线或以上化疗失败的晚期胃癌具有良好的疗效和安全性。
|
| 关 键 词： | 胃癌 甲磺酸阿帕替尼 靶向治疗 |
Clinic observation of apatinib in treatment of advancedgastric carcinoma |
| |
| Han Tingting1,Shi Mingwei2,Wang Fan1,Wang Yingjie3. Clinic observation of apatinib in treatment of advancedgastric carcinoma[J]. Journal of Modern Oncology, 2018, 0(4): 557-559. DOI: 10.3969/j.issn.1672-4992.2018.04.018 |
| |
| Authors: | Han Tingting1 Shi Mingwei2 Wang Fan1 Wang Yingjie3 |
| |
| Affiliation: | 1.Department of Radiation Oncology，The First Affiliated Hospital of Anhui Medical University，Anhui Hefei 230022，China;2.Department of Oncology，Cancer Hospital，Chinese Academy of Sciences，Anhui Hefei 230031，China;3.Department of Radiation Oncology，Air Forc |
| |
| Abstract: | Objective:To evaluate the efficacy and toxicity of apatinib mesylate in treatment of advanced gastric carcinoma.Mathods:Twenty-eight patients with treatment of advanced gastric carcinoma were recruited from Janurary 2016 to February 2017.All patients were received apatinib mesylate 500 mg/d orally until disease progression or intolerable toxicity.Clinical efficacy and adverse reactions were observed.Results:The total response rate and disease control rate was 10.7% and 42.8%.Median local progression-free survival and median overall survival was 3.6 months and 5 months.Apatinib mesylate was well tolerated without severe toxicities.The main adverse reactions were hypertension，hand-footsyndrome，proteinuria，mostly degree Ⅰor Ⅱ.Conclusion:Apatinib mesylate is effective and tolerable for advanced gastric carcinoma patients that failed second-line or above chemotherapy. |
| |
| Keywords: | gastric carcinoma apatinib mesylate targeted therapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
